title: Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential.
authors: Department of Psychiatry, University of Vermont, Burlington, VT, USA.
authors: Stacey C
authors: SC
authors: Sigmon
authors: Behavioral Pharmacology Research Unit, Johns Hopkins University, Baltimore, MD, USA.
authors: George E
authors: GE
authors: Bigelow
mesh_terms: D002047:Buprenorphine / Q000008:administration & dosage / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D006801:Humans; D009292:Narcotic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D058850:Opiate Substitution Treatment / Q000379:methods*; D009293:Opioid-Related Disorders / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D003692:Delayed-Action Preparations; D009292:Narcotic Antagonists; D002047:Buprenorphine
keywords: Buprenorphine; implant; medication-assisted treatment; opioid; opioid use disorder; sustained-release